Read here for an insight from the STV News show, Scotland Tonight, with our CEO and Founder, Prof Craig Ritchie, about the lifechanging potential for research to help detect Alzheimer’s early & treat before it progresses to dementia.
Diagnosis, treatment, outputs from research initiatives, trials (excluding sport) and explainers/fact sheets
Please join us in welcoming Dr Sarah Gregory to the SBS Team as IONA National Coordinator! Read more about what she brings to Scottish Brain Sciences…
We are thrilled to be able to welcome Dr Clara Russell to the SBS Team as Senior Clinical Investigator! Read more about what she brings to Scottish Brain Sciences…
An agreement between Scottish Brain Sciences and a global leader in precision diagnostics is aiming to transform the ability of clinicians to identify the very earliest signs of Alzheimer’s Disease – long before symptoms can be seen.
Professor Craig Ritchie has told an international Alzheimer’s conference that phase 3 clinical trial results for donanemab, the antibody drug designed to target and clear the amyloid plaques considered key to progression of Alzheimer’s disease, reveal the drug’s “profound” clinical effect.
With the publication of Scotland’s new dementia strategy, the government’s Chief Scientist for Health, Professor Anna Dominiczack says it is now an important time to help make life-changing discoveries – encouraging Scots to volunteer for research into progressive brain conditions.
With visits to both Boston, Massachusetts for the BIO Convention, as well as San Francisco, California, for an exciting Life Sciences reception, June 2023 was a big month for Scottish Brain Sciences. And one that also promised big things on the horizon!
New insights from research led by the University of Edinburgh reveal that the structures sending neurological signals and supporting normal brain function also enable the build-up of toxic proteins linked to Alzheimer’s disease – a finding which they say could prove vital in the search for therapies for slowing the progression of Alzheimer’s disease.
Roche has announced its collaboration with its counterpart Eli Lilly to try to achieve early diagnosis of Alzheimer’s disease using the diagnostic Elecsys Amyloid Plasma Panel – testing blood plasma for key Alzheimer’s disease markers.
A World Dementia Council Summit will this week (Monday) discuss how teams conducting clinical research into Alzheimer’s disease and wider dementia can measure what matters when some interventions clearly benefit patients but may not deliver the dramatic improvements needed to meet current definitions of effectiveness.